Chugai Pharmaceutical
Clinical trials sponsored by Chugai Pharmaceutical, explained in plain language.
-
New drug targets immune overdrive in six rare diseases
Disease control Recruiting nowThis early-stage trial is testing a drug called RAY121 in 144 people with one of six immune diseases, including antiphospholipid syndrome and bullous pemphigoid. The drug works by blocking a specific part of the immune system (the complement pathway) that can cause tissue damage.…
Phase: PHASE1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers? first human trial of AUBE00 begins
Disease control Recruiting nowThis early-stage study tests a new drug, AUBE00, in about 90 to 130 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants must have a spec…
Phase: PHASE1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New hope for celiac sufferers: drug targets gut damage despite strict diet
Disease control Recruiting nowThis study tests an experimental drug called DONQ52 in people with active celiac disease who still have gut damage and symptoms even after following a gluten-free diet for at least a year. About 92 adults will receive either the drug or a placebo to see if it can heal the small i…
Phase: PHASE2 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New hope for tough lung cancer: ALPS12 drug trial begins
Disease control Recruiting nowThis early-phase study tests a new drug called ALPS12 in people with extensive-stage small cell lung cancer that has returned after prior treatment. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 122 participants will ta…
Phase: PHASE1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC